We think current share prices do not properly account for expected price declines and competition, let alone the risk of patients discontinuing therapy due to tolerability, cost, or long-term safety issues
As a brief aside, this distinction maps neatly onto what we know about muscle fiber types
A recent study found that more than 50% of people who stopped taking their GLP-1 were able to keep their weight off or continue losing weight after one year
Garczorz W, Gallego-Colon E, Kosowska A, Kych-Ratuszny A, Woniak M, Marcol W, et al
If those dont work, they might then approve a newer drug like Wegovy
Edison, P